{
    "Rank": 966,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT00075673",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "ICC3102"
                },
                "Organization": {
                    "OrgFullName": "Case Comprehensive Cancer Center",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer",
                "OfficialTitle": "A Phase I Study of Weekly Administration of Oral Navelbine in Combination With the COX-2 Inhibitor Celebrex in Relapsed and/or Metastatic Breast Cancer"
            },
            "StatusModule": {
                "StatusVerifiedDate": "July 2020",
                "OverallStatus": "Terminated",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "November 2003"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "September 2004",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "February 2005",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "January 9, 2004",
                "StudyFirstSubmitQCDate": "January 11, 2004",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "January 12, 2004",
                    "StudyFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "July 23, 2020",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "July 27, 2020",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyOldNameTitle": "Paula Silverman, MD",
                    "ResponsiblePartyOldOrganization": "Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Case Comprehensive Cancer Center",
                    "LeadSponsorClass": "OTHER"
                }
            },
            "OversightModule": {
                "OversightHasDMC": "Yes"
            },
            "DescriptionModule": {
                "BriefSummary": "RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy, such as vinorelbine, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining vinorelbine with celecoxib may kill more tumor cells.\n\nPURPOSE: Phase I trial to determine the effectiveness of combining vinorelbine with celecoxib in treating women who have relapsed or metastatic breast cancer.",
                "DetailedDescription": "OBJECTIVES:\n\nDetermine the maximum tolerated dose of vinorelbine and celecoxib in women with relapsed or metastatic breast cancer.\nDetermine the safety profile of this regimen in these patients.\n\nOUTLINE: This is a dose-escalation study.\n\nPatients receive oral celecoxib twice daily on days 1-21 and oral vinorelbine on days 7, 14, and 21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nCohorts of 3-6 patients receive escalating doses of celecoxib and vinorelbine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.\n\nPROJECTED ACCRUAL: A total of 12-18 patients will be accrued for this study."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Breast Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "recurrent breast cancer",
                        "stage IV breast cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 1"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "N/A",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "6",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "celecoxib",
                            "InterventionDescription": "Patients receive oral celecoxib twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
                        },
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "vinorelbine ditartrate",
                            "InterventionDescription": "Patients receive oral vinorelbine on days 7, 14, and 21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Determine the maximum tolerated dose of vinorelbine and celecoxib in women with relapsed or metastatic breast cancer.",
                            "PrimaryOutcomeTimeFrame": "Courses (21 days) repeat every 21 days in the absence of disease progression or unacceptable toxicity."
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "DISEASE CHARACTERISTICS:\n\nHistologically confirmed adenocarcinoma of the breast\n\nRecurrent or metastatic (stage IV) disease\nIncurable disease\nMeasurable or evaluable disease\nStable brain metastases allowed\n\nHormone receptor status:\n\nNot specified\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n18 and over\n\nSex\n\nFemale\n\nMenopausal status\n\nNot specified\n\nPerformance status\n\nECOG 0-1\n\nLife expectancy\n\nMore than 3 months\n\nHematopoietic\n\nAbsolute neutrophil count \u2265 1,500/mm^3\nPlatelet count \u2265 100,000/mm^3\nHemoglobin \u2265 8.0 g/dL\n\nHepatic\n\nBilirubin normal\nAST/ALT \u2264 2.5 times upper limit of normal\n\nRenal\n\nCreatinine normal OR\nCreatinine clearance \u2265 60 mL/min\nNo clinically significant proteinuria\nNo impaired renal function\n\nCardiovascular\n\nNo symptomatic congestive heart failure\nNo unstable angina\nNo cardiac arrhythmia\nNo inadequately controlled hypertension\n\nGastrointestinal\n\nNo disorder that would alter gastrointestinal motility or absorption\nNo dysphagia\nAble to swallow tablets or capsules\n\nOther\n\nNot pregnant or nursing\nNegative pregnancy test\nFertile patients must use effective contraception\n\nNo hypersensitivity to celecoxib\n\nNo prior urticaria, asthma, or other allergic-type reaction after taking aspirin or other nonsteroidal anti-inflammatory drugs\nNo allergy to sulfa\nNo other concurrent uncontrolled illness\nNo psychiatric illness or social situation that would preclude study compliance\nNo ongoing or active infection\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nAt least 3 weeks since prior trastuzumab (Herceptin\u00ae) and recovered\nNo concurrent hematopoietic growth factors\n\nChemotherapy\n\nAt least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered\nPrior adjuvant or neoadjuvant chemotherapy allowed\nPrior chemotherapy for recurrent or metastatic disease allowed\nNo prior vinorelbine\n\nEndocrine therapy\n\nAt least 2 weeks since prior hormonal therapy\nPrior adjuvant or neoadjuvant hormonal therapy allowed\nPrior hormonal therapy for recurrent or metastatic disease allowed\n\nRadiotherapy\n\nAt least 4 weeks since prior radiotherapy for metastatic disease\nPrior adjuvant radiotherapy allowed\n\nSurgery\n\nNot specified\n\nOther\n\nAt least 3 weeks since prior investigational anticancer agents and recovered\nAt least 1 week since prior cyclooxygenase-2 (COX-2) inhibitors, except celecoxib\n\nNo concurrent administration of any of the following drugs:\n\nLithium\nFluconazole\nAluminum antacids\nMagnesium antacids\nConcurrent H_2 blocking agents or proton pump inhibitors allowed for the treatment of dyspepsia or gastroesophageal reflux disease\nConcurrent bisphosphonates allowed",
                "HealthyVolunteers": "No",
                "Gender": "Female",
                "MinimumAge": "18 Years",
                "MaximumAge": "120 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Paula Silverman, MD",
                            "OverallOfficialAffiliation": "Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center",
                            "LocationCity": "Cleveland",
                            "LocationState": "Ohio",
                            "LocationZip": "44106-5055",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000001943",
                            "ConditionMeshTerm": "Breast Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000001941",
                            "ConditionAncestorTerm": "Breast Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000012871",
                            "ConditionAncestorTerm": "Skin Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M4910",
                            "ConditionBrowseLeafName": "Breast Neoplasms",
                            "ConditionBrowseLeafAsFound": "Breast Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M14540",
                            "ConditionBrowseLeafName": "Recurrence",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M4908",
                            "ConditionBrowseLeafName": "Breast Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M15364",
                            "ConditionBrowseLeafName": "Skin Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC17",
                            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC23",
                            "ConditionBrowseBranchName": "Symptoms and General Pathology"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionMeshList": {
                    "InterventionMesh": [
                        {
                            "InterventionMeshId": "D000068579",
                            "InterventionMeshTerm": "Celecoxib"
                        },
                        {
                            "InterventionMeshId": "D000077235",
                            "InterventionMeshTerm": "Vinorelbine"
                        }
                    ]
                },
                "InterventionAncestorList": {
                    "InterventionAncestor": [
                        {
                            "InterventionAncestorId": "D000000894",
                            "InterventionAncestorTerm": "Anti-Inflammatory Agents, Non-Steroidal"
                        },
                        {
                            "InterventionAncestorId": "D000018712",
                            "InterventionAncestorTerm": "Analgesics, Non-Narcotic"
                        },
                        {
                            "InterventionAncestorId": "D000000700",
                            "InterventionAncestorTerm": "Analgesics"
                        },
                        {
                            "InterventionAncestorId": "D000018689",
                            "InterventionAncestorTerm": "Sensory System Agents"
                        },
                        {
                            "InterventionAncestorId": "D000018373",
                            "InterventionAncestorTerm": "Peripheral Nervous System Agents"
                        },
                        {
                            "InterventionAncestorId": "D000045505",
                            "InterventionAncestorTerm": "Physiological Effects of Drugs"
                        },
                        {
                            "InterventionAncestorId": "D000000893",
                            "InterventionAncestorTerm": "Anti-Inflammatory Agents"
                        },
                        {
                            "InterventionAncestorId": "D000018501",
                            "InterventionAncestorTerm": "Antirheumatic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000052246",
                            "InterventionAncestorTerm": "Cyclooxygenase 2 Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000016861",
                            "InterventionAncestorTerm": "Cyclooxygenase Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000004791",
                            "InterventionAncestorTerm": "Enzyme Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000045504",
                            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                        },
                        {
                            "InterventionAncestorId": "D000000972",
                            "InterventionAncestorTerm": "Antineoplastic Agents, Phytogenic"
                        },
                        {
                            "InterventionAncestorId": "D000000970",
                            "InterventionAncestorTerm": "Antineoplastic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000050257",
                            "InterventionAncestorTerm": "Tubulin Modulators"
                        },
                        {
                            "InterventionAncestorId": "D000050256",
                            "InterventionAncestorTerm": "Antimitotic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000050258",
                            "InterventionAncestorTerm": "Mitosis Modulators"
                        }
                    ]
                },
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M1710",
                            "InterventionBrowseLeafName": "Vinorelbine",
                            "InterventionBrowseLeafAsFound": "Allogeneic",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M277",
                            "InterventionBrowseLeafName": "Celecoxib",
                            "InterventionBrowseLeafAsFound": "Locally",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M26699",
                            "InterventionBrowseLeafName": "Cyclooxygenase 2 Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M3907",
                            "InterventionBrowseLeafName": "Anti-Inflammatory Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M3908",
                            "InterventionBrowseLeafName": "Anti-Inflammatory Agents, Non-Steroidal",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M3722",
                            "InterventionBrowseLeafName": "Analgesics",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M20476",
                            "InterventionBrowseLeafName": "Analgesics, Non-Narcotic",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M20294",
                            "InterventionBrowseLeafName": "Antirheumatic Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M18899",
                            "InterventionBrowseLeafName": "Cyclooxygenase Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M7641",
                            "InterventionBrowseLeafName": "Enzyme Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M25887",
                            "InterventionBrowseLeafName": "Tubulin Modulators",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M25886",
                            "InterventionBrowseLeafName": "Antimitotic Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "ANeo",
                            "InterventionBrowseBranchName": "Antineoplastic Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "Infl",
                            "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "ARhu",
                            "InterventionBrowseBranchName": "Antirheumatic Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "Analg",
                            "InterventionBrowseBranchName": "Analgesics"
                        }
                    ]
                }
            }
        }
    }
}